Sei Investments Co. Has $879,000 Position in Castle Biosciences, Inc. (NASDAQ:CSTL)

Sei Investments Co. raised its holdings in Castle Biosciences, Inc. (NASDAQ:CSTL) by 32.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 17,071 shares of the company’s stock after buying an additional 4,199 shares during the period. Sei Investments Co. owned 0.08% of Castle Biosciences worth $879,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. Wasatch Advisors Inc. increased its stake in Castle Biosciences by 26.2% in the 3rd quarter. Wasatch Advisors Inc. now owns 1,378,057 shares of the company’s stock valued at $70,901,000 after buying an additional 286,275 shares during the last quarter. BlackRock Inc. increased its stake in Castle Biosciences by 21.6% in the 3rd quarter. BlackRock Inc. now owns 999,662 shares of the company’s stock valued at $51,433,000 after buying an additional 177,685 shares during the last quarter. RTW Investments LP increased its stake in Castle Biosciences by 15.1% in the 2nd quarter. RTW Investments LP now owns 803,510 shares of the company’s stock valued at $30,284,000 after buying an additional 105,392 shares during the last quarter. Wells Fargo & Company MN increased its stake in Castle Biosciences by 8.3% in the 3rd quarter. Wells Fargo & Company MN now owns 603,531 shares of the company’s stock valued at $31,052,000 after buying an additional 46,058 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in Castle Biosciences by 146.8% in the 2nd quarter. Vanguard Group Inc. now owns 541,749 shares of the company’s stock valued at $20,418,000 after buying an additional 322,259 shares during the last quarter. Hedge funds and other institutional investors own 60.95% of the company’s stock.

Shares of Castle Biosciences stock opened at $67.15 on Friday. The company has a 50 day moving average of $56.61 and a 200-day moving average of $48.36. Castle Biosciences, Inc. has a 1-year low of $21.01 and a 1-year high of $78.39. The company has a current ratio of 6.65, a quick ratio of 6.59 and a debt-to-equity ratio of 0.07. The company has a market cap of $1.35 billion, a PE ratio of -394.98 and a beta of 0.35.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Saturday, November 14th. The company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.12). The firm had revenue of $15.22 million for the quarter, compared to the consensus estimate of $15.31 million. Castle Biosciences had a negative return on equity of 2.69% and a negative net margin of 5.30%. Research analysts forecast that Castle Biosciences, Inc. will post -0.4 earnings per share for the current year.

In other Castle Biosciences news, insider Derek J. Maetzold sold 6,250 shares of the company’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $47.52, for a total value of $297,000.00. Following the completion of the transaction, the insider now directly owns 1,408,748 shares in the company, valued at approximately $66,943,704.96. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Frank Stokes sold 13,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The shares were sold at an average price of $54.79, for a total transaction of $712,270.00. Following the completion of the transaction, the chief financial officer now owns 14,886 shares of the company’s stock, valued at $815,603.94. The disclosure for this sale can be found here. In the last three months, insiders sold 414,542 shares of company stock valued at $23,189,104. 39.70% of the stock is owned by insiders.

Several equities research analysts have issued reports on CSTL shares. Zacks Investment Research lowered shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, November 12th. KeyCorp assumed coverage on shares of Castle Biosciences in a research note on Monday, November 9th. They set an “overweight” rating and a $70.00 price objective on the stock. Canaccord Genuity boosted their price objective on shares of Castle Biosciences from $52.00 to $61.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. BidaskClub upgraded shares of Castle Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 15th. Finally, SVB Leerink boosted their price objective on shares of Castle Biosciences from $57.00 to $70.00 and gave the stock an “outperform” rating in a research note on Friday, December 11th. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Castle Biosciences currently has an average rating of “Buy” and an average price target of $62.83.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue.

Read More: Shanghai Stock Exchange Composite Index

Institutional Ownership by Quarter for Castle Biosciences (NASDAQ:CSTL)

Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.